| Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ:MRVI). Investors who purchased Maravai securities prior to August 7, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRVI. |
accessnewswire.com |
2025-05-15 14:00:00 |
Czytaj oryginał (ang.) |
| These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results |
Maravai LifeSciences Holdings, Inc. MRVI reported mixed results for the first quarter on Monday. |
benzinga.com |
2025-05-13 17:29:22 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ:MRVI). Investors who purchased Maravai securities prior to August 7, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRVI. |
accessnewswire.com |
2025-05-13 14:00:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2025 Earnings Call Transcript |
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Debra Hart - Head, IR Kevin Herde - EVP and CFO Trey Martin - CEO Becky Buzzeo - EVP & CCO Conference Call Participants Conor McNamara - RBC Capital Markets Daniel Arias - Stifel Tejas Savant - Morgan Stanley Matthew Stanton - Jeffries Brandon Coulliard - Wells Fargo Matthew Hewitt - Craig-Hallum Operator Please stand by, we're about to begin. Good afternoon, everyone, and welcome to the Maravai LifeSciences Q1 2025 Results Earnings Call. |
seekingalpha.com |
2025-05-13 04:03:03 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q1 Loss, Tops Revenue Estimates |
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.02 per share a year ago. |
zacks.com |
2025-05-12 22:20:37 |
Czytaj oryginał (ang.) |
| Maravai Lifesciences Reports First Quarter 2025 Financial Results |
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. |
globenewswire.com |
2025-05-12 20:06:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ:MRVI). Investors who purchased Maravai securities prior to August 7, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRVI. |
accessnewswire.com |
2025-05-11 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Investors to Reach Out |
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ:MRVI). Investors who purchased Maravai securities prior to August 7, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRVI. |
accessnewswire.com |
2025-05-08 14:00:00 |
Czytaj oryginał (ang.) |
| Contact Levi & Korsinsky by May 5, 2025 Deadline to Join Class Action Against Maravai LifeSciences Holdings, Inc. (MRVI) |
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/maravai-lifesciences-holdings-inc-lawsuit-submission-form?prid=147042&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-05 20:30:00 |
Czytaj oryginał (ang.) |
| MRVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) (NASDAQ: MRVI) and certain of its officers. |
globenewswire.com |
2025-05-05 20:00:00 |
Czytaj oryginał (ang.) |
| Investors in Maravai LifeSciences Holdings, Inc. Should Contact Levi & Korsinsky Before May 5, 2025 to Discuss Your Rights - MRVI |
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/maravai-lifesciences-holdings-inc-lawsuit-submission-form?prid=147028&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-05 19:00:00 |
Czytaj oryginał (ang.) |
| Investors who lost money on Maravai LifeSciences Holdings, Inc.(MRVI) should contact Levi & Korsinsky about pending Class Action - MRVI |
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit. |
globenewswire.com |
2025-05-05 17:48:00 |
Czytaj oryginał (ang.) |
| Class Action Filed Against Maravai LifeSciences Holdings, Inc. (MRVI) - May 5, 2025 Deadline to Join - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/maravai-lifesciences-holdings-inc-lawsuit-submission-form?prid=146986&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-05 15:30:00 |
Czytaj oryginał (ang.) |
| MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm |
LOS ANGELES--(BUSINESS WIRE)--MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm. |
businesswire.com |
2025-05-05 15:10:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI |
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. |
globenewswire.com |
2025-05-05 15:01:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 5, 2025 to Discuss Your Rights - MRVI |
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/maravai-lifesciences-holdings-inc-lawsuit-submission-form?prid=146950&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-05 13:30:00 |
Czytaj oryginał (ang.) |
| MRVI DEADLINE TODAY: Maravai LifeSciences (MRVI) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action |
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) reported its fourth-quarter 2024 earnings, missing analyst expectations and prompting a significant downward revision of its price target by at least one firm. The company is also facing a securities class action lawsuit alleging improper accounting. |
globenewswire.com |
2025-05-05 13:18:00 |
Czytaj oryginał (ang.) |
| MRVI Investors Reminded of Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm |
LOS ANGELES , May 5, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ: MRVI) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 7, 2024 and February 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 5, 2025. |
prnewswire.com |
2025-05-05 13:09:00 |
Czytaj oryginał (ang.) |
| Investors in Maravai LifeSciences Holdings, Inc. Should Contact Levi & Korsinsky Before May 5, 2025 to Discuss Your Rights - MRVI |
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/maravai-lifesciences-holdings-inc-lawsuit-submission-form?prid=146916&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-05 11:25:00 |
Czytaj oryginał (ang.) |
| FINAL REMINDER MRVI DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Maravai LifeSciences Holdings, Inc. Investors to Participate in the Class Action Lawsuit |
NEW YORK CITY, NY / ACCESS Newswire / May 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ:MRVI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Maravai securities between August 7, 2024 and February 24, 2025, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Holdings, Inc. (MRVI) Shares Fall 21% After Delaying Q4 and FY 2024 Earnings Release, Admitting to Improper Revenue Recognition – Hagens Berman |
SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- On February 25, 2025, the share price of Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plummeted 21% after the company announced it is delaying its Q4 and FY 2024 earnings release and said it requires additional time to complete its year-end financial close process. |
globenewswire.com |
2025-02-27 21:55:00 |
Czytaj oryginał (ang.) |
| MRVI INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Maravai LifeSciences Holdings, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm |
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Maravai investigation or if you are a Maravai investor who suffered a loss and would lik. |
businesswire.com |
2025-02-27 17:33:00 |
Czytaj oryginał (ang.) |
| Did Maravai LifeSciences Holdings, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - MRVI |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences Holdings, Inc.") (NASDAQ:MRVI) concerning possible violations of federal securities laws. Maravai LifeSciences Holdings had postponed its Q4 and FY24 earnings release and delayed filing its Form 10-K. |
accessnewswire.com |
2025-02-26 22:15:00 |
Czytaj oryginał (ang.) |
| Kirby McInerney LLP Announces Investigation Against Maravai Lifesciences Holdings, Inc. (MRVI) on Behalf of Investors |
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Maravai Lifesciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ:MRVI). The investigation concerns whether Maravai and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. |
globenewswire.com |
2025-02-26 22:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Maravai LifeSciences Holdings, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - MRVI |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences Holdings, Inc.") (NASDAQ:MRVI) concerning possible violations of federal securities laws. Maravai LifeSciences Holdings had postponed its Q4 and FY24 earnings release and delayed filing its Form 10-K. |
accessnewswire.com |
2025-02-26 17:30:00 |
Czytaj oryginał (ang.) |
| MRVI ALERT: Maravai Lifesciences Holdings Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm |
BOSTON, MA / ACCESS Newswire / February 26, 2025 / Block & Leviton is investigating Maravai Lifesciences Holdings, Inc (Nasdaq:MRVI) for potential securities law violations. Investors who have lost money in their Maravai Lifesciences Holdings, Inc investment should contact the firm to learn more about how they might recover those losses. |
accessnewswire.com |
2025-02-26 12:30:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Securities Fraud Investigation: Investors Urged to Contact Award-Winning Firm, Gibbs Law Group LLP |
OAKLAND, Calif.--(BUSINESS WIRE)---- $MRVI #MRVI--Gibbs Law Group announces a legal investigation on behalf of Maravai LifeSciences investors. |
businesswire.com |
2025-02-25 23:13:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Holdings, Inc. (MRVI) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation |
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith t. |
businesswire.com |
2025-02-25 20:40:00 |
Czytaj oryginał (ang.) |
| Securities Fraud Investigation Into Maravai LifeSciences Holdings, Inc. (MRVI) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz |
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 25, 2025, Maravai dis. |
businesswire.com |
2025-02-25 18:32:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Holdings Stock Alert - Company Will Delay Earnings Release - Kehoe Law Firm, P.C. Investigating Potential Securities Claims - MRVI |
PHILADELPHIA, PA / ACCESS Newswire / February 25, 2025 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences," "Maravai," or the "Company") (NASDAQ:MRVI) investors. |
accessnewswire.com |
2025-02-25 13:15:00 |
Czytaj oryginał (ang.) |
| MRVI DOWN 24%: Maravai Lifesciences Under Investigation for Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses |
BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Maravai Lifesciences Holdings, Inc (Nasdaq: MRVI) for potential securities law violations. Investors who have lost money in their Maravai Lifesciences Holdings, Inc investment should contact the firm to learn more about how they might recover those losses. |
globenewswire.com |
2025-02-25 13:08:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call |
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and call scheduled for February 25, 2025. It also announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission and will delay the filing its annual report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”). Maravai intends to hold its postponed earnings call and to file the 2024 Form 10-K as soon as practicable and on or before March 18, 2025, prior to the expiration of the automatic extension of fifteen calendar days from the original 2024 Form 10-K due date of March 3, 2025. |
globenewswire.com |
2025-02-25 08:00:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio |
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio's DNA and RNA business. This acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities, providing customers comprehensive expertise and n. |
businesswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology |
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide gr. |
businesswire.com |
2025-02-04 18:01:00 |
Czytaj oryginał (ang.) |
| TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe |
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has partnered with, Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, to expand availability of its innovative nucleic acid products to customers across Europe, Middle East, and Africa (EMEA). This distribution pa. |
businesswire.com |
2025-02-03 08:00:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue |
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that based on preliminary year-end results and subject to year-end closing adjustments, the Company expects to report total 2024 revenue near the mid-point of the previously announced guidance range of $255.0 million and $265.0 million. The Company also announced that it plans to announce its fourth quarter and full year 2024 financial and operating results after the market closes on Tuesday, February 25, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. |
globenewswire.com |
2025-01-08 18:10:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors |
SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. |
globenewswire.com |
2024-12-05 18:05:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Announces November 2024 Investor Conference Schedule |
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November. |
globenewswire.com |
2024-11-12 10:05:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2024 Earnings Call Transcript |
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Deb Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - EVP and Chief Financial Officer Drew Burch - President, Nucleic Acid Production Conference Call Participants Dan Leonard - UBS Justin Bowers - Deutsche Bank Yuko Oku - Morgan Stanley Matt Hewitt - Craig-Hallum Dan Arias - Stifel Operator Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. |
seekingalpha.com |
2024-11-09 20:45:06 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024 |
SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. |
globenewswire.com |
2024-10-15 20:05:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits |
MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity. |
zacks.com |
2024-08-29 14:25:45 |
Czytaj oryginał (ang.) |
| Exclusive: Repligen in bid for reagent vendor Maravai, sources say |
Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday. |
reuters.com |
2024-08-16 15:46:16 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Announces August and September 2024 Investor Conference Schedule |
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September. |
globenewswire.com |
2024-08-12 12:05:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2024 Earnings Call Transcript |
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2024 Results Conference Call August 7, 2024 5:00 PM ET Company Participants Deborah Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Chief Commercial Officer Conference Call Participants Catherine Schulte - Baird Tejas Savant - Morgan Stanley Matt Hewitt - Craig-Hallum Justin Bowers - Deutsche Bank Conor McNamara - RBC Capital Markets Michael Ryskin - Bank of America Matt Larew - William Blair Kyle Crews - UBS Operator Thank you for standing by and welcome to the Maravai LifeSciences Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. |
seekingalpha.com |
2024-08-08 10:19:09 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024 |
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. |
globenewswire.com |
2024-07-10 12:00:00 |
Czytaj oryginał (ang.) |
| Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report |
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. |
globenewswire.com |
2024-07-02 20:00:00 |
Czytaj oryginał (ang.) |
| Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics |
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability - - Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand - STONY BROOK, NY AND JUPITER, FL / ACCESSWIRE / June 20, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (NASDAQ:MRVI) and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies' previously announced Linea™ RNAP manufacturing scale-up agreement. The joint process development project resulted in an over 70% reduction in Linea RNAP manufacturing costs and the manufacture of a quantity of Linea RNAP sufficient to support Applied DNA's anticipated near-term demand for critical starting material for mRNA production. |
accesswire.com |
2024-06-20 13:15:00 |
Czytaj oryginał (ang.) |
| Maravai (MRVI) Advances in RNA Research With New Collaboration |
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies. |
zacks.com |
2024-05-17 16:56:05 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule |
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the months of May and June. |
globenewswire.com |
2024-05-09 20:05:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2024 Earnings Call Transcript |
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Debbie Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Chief Commercial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Tejas Savant - Morgan Stanley Dan Leonard - UBS Tom Peterson - Baird Matt Larew - William Blair Bob Yan - Bank of America Securities Operator Good day, ladies and gentlemen. And welcome to the First Quarter 2024 Maravai LifeSciences Earnings Conference Call. |
seekingalpha.com |
2024-05-09 00:59:08 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Reports First Quarter 2024 Financial Results |
Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation |
globenewswire.com |
2024-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology |
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology. |
businesswire.com |
2024-04-30 11:31:00 |
Czytaj oryginał (ang.) |
| TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production |
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production. |
businesswire.com |
2024-04-18 11:36:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024 |
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. |
globenewswire.com |
2024-04-10 20:05:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Announces March 2024 Investor Conference Schedule |
SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of March. |
globenewswire.com |
2024-03-12 18:15:00 |
Czytaj oryginał (ang.) |
| Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2023 Earnings Call Transcript |
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-02-23 02:00:23 |
Czytaj oryginał (ang.) |